Crystallographic analysis of an 8-mer p53 peptide analogue complexed with MDM2

被引：48

作者：

Sakurai, Kaori

Schubert, Carsten

Kahne, Daniel

机构：

[1] Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA

[2] Johnson & Johnson Pharmaceut Res & Dev LLC, Exton, PA 19341 USA

[3] Harvard Univ, Sch Med, Dept Biol Cellular & Mol Pharmacol, Boston, MA 02115 USA

来源：

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY | 2006年 / 128卷 / 34期

关键词：

D O I：

10.1021/ja063102j

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The most potent inhibitor of the p53-MDM2 interaction reported to date is an 8-mer p53 peptide analogue (Novartis peptide), which contains 6-chlorotryptophane (Cl-Trp) and phosphonomethylphenylalanine (Pmp) as key residues for the enhanced activity. We report here a crystal structure of the co-complex between MDM2 and the Novartis peptide solved at 1.8 Å resolution. The structural basis for the role of the two aromatic residues are delineated by comparing the present structure with crystal structures of the MDM2 co-complex bound to other inhibitors including the wt-p53 peptide itself. Copyright © 2006 American Chemical Society.

引用

收藏

页码：11000 / 11001

页数：2

相关论文

共 21 条

[1]

Bottger V, 1996, ONCOGENE, V13, P2141

[2] A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines [J].

Chène, P ;

Fuchs, J ;

Bohn, J ;

García-Echeverría, C ;

Furet, P ;

Fabbro, D .

JOURNAL OF MOLECULAR BIOLOGY, 2000, 299 (01) :245-253

[3] Inhibiting the p53-MDM2 interaction:: An important target for cancer therapy [J].

Chène, P .

NATURE REVIEWS CANCER, 2003, 3 (02) :102-109

[4] Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? [J].

Fischer, PM ;

Lane, DP .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (07) :343-346

[5] Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53 [J].

García-Echeverría, C ;

Chène, P ;

Blommers, MJJ ;

Furet, P .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (17) :3205-3208

[6]

GELLMAN SH, 2005, J AM CHEM SOC, V127, P13271

[7] Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells [J].

Grasberger, BL ;

Lu, TB ;

Schubert, C ;

Parks, DJ ;

Carver, TE ;

Koblish, HK ;

Cummings, MD ;

LaFrance, LV ;

Milkiewicz, KL ;

Calvo, RR ;

Maguire, D ;

Lattanze, J ;

Franks, CF ;

Zhao, SY ;

Ramachandren, K ;

Bylebyl, GR ;

Zhang, M ;

Manthey, CL ;

Petrella, EC ;

Pantoliano, MW ;

Deckman, IC ;

Spurlino, JC ;

Maroney, AC ;

Tomczuk, BE ;

Molloy, CJ ;

Bone, RF .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (04) :909-912

[8] Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions [J].

Hara, T ;

Durell, SR ;

Myers, MC ;

Appella, DH .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (06) :1995-2004

[9] A rapid library screen for tailoring β-peptide structure and function [J].

Kritzer, JA ;

Luedtke, NW ;

Harker, EA ;

Schepartz, A .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2005, 127 (42) :14584-14585

[10] Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain [J].

Kussie, PH ;

Gorina, S ;

Marechal, V ;

Elenbaas, B ;

Moreau, J ;

Levine, AJ ;

Pavletich, NP .

SCIENCE, 1996, 274 (5289) :948-953